Forward-Looking Statements

This presentation by TherapeuticsMD, Inc. (referred to as “we,” “our,” or the “Company”) may contain forward-looking statements. Forward-looking statements may include, but are not limited to, statements relating to our objectives, plans and strategies, other than historical facts, that address activities, events or developments that we intend, expect, or anticipate will or may occur in the future. These statements are often characterized by terminology such as “believe,” “hope,” “may,” “anticipate,” “should,” “intend,” “plan,” “will,” “expect,” “estimate,” “project,” “positioned,” “strategy” and similar expressions and are based on assumptions and assessments made in light of our managerial experience and perception of historical trends, current conditions, expected future developments and other factors we believe to be appropriate.

Forward-looking statements in this presentation are made as of the date of this presentation, and we undertake no duty to update or revise any such statements, whether as a result of new information, future events or otherwise. Forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties, many of which may be outside of our control. Important factors that could cause actual results, developments and business decisions to differ materially from forward-looking statements are described in the sections titled “Risk Factors” in our filings with the Securities and Exchange Commission (SEC), including our most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, as well as our current reports on Form 8-K, and include the following: the effects of the COVID-19 pandemic; whether the company will meet the anticipated and/or projected 2021 and later performance measures that are included in this presentation for informational purposes; the company’s ability to maintain or increase sales of its products; the company’s ability to develop and commercialize Imvexxy®, ANNOVERA®, and Bijuva® and obtain additional financing necessary therefor; whether the company will be able to comply with the covenants and conditions under its term loan facility, including the minimum net revenue and minimum cash covenants; whether the company will be able to successfully divest its vitaCare business and how the proceeds that may be generated by such divestiture will be used; the potential of adverse side effects or other safety risks that could adversely affect the commercialization of the company’s current or future approved products or preclude the approval of the company’s future drug candidates; whether the FDA will approve the lower dose of Bijuva; the company’s ability to protect its intellectual property, including with respect to the Paragraph IV notice letters the company received regarding Imvexxy and Bijuva; the length, cost and uncertain results of future clinical trials; the company’s reliance on third parties to conduct its manufacturing, research and development and clinical trials; the ability of the company’s licensees to commercialize and distribute the company’s products; the ability of the company’s marketing contractors to market ANNOVERA; the availability of reimbursement from government authorities and health insurance companies for the company’s products; the ability to grow the company’s vitaCare business; the impact of product liability lawsuits; the influence of extensive and costly government regulation; the volatility of the trading price of the company’s common stock and the concentration of power in its stock ownership. This non-promotional presentation is intended for investor audiences only.
Strategic Overview
Overview of 2020 Accomplishments During a Challenging Year

✔ Delivered strong growth in 2020 and Q4

✔ Improved key financial metrics and took action to strengthen balance sheet
  − Increased 4Q20 net product revenue 30% to $22.6M compared to 3Q20
    − ANNOVERA net revenue per unit above expectations
  − Completed transformative equity capital raises in 4Q20 and 1Q21
  − Updated Sixth Street loan revenue covenants

✔ Focused on financial discipline and demonstrated operational agility while navigating through global pandemic

✔ vitaCare divestiture process moving forward
Strengthened Balance Sheet and Revised Covenants

Strengthened Balance Sheet
- Improved our cash balance through a $180M series of transformative equity capital raises in 4Q20 and 1Q21 which increased our cash balance to >$200M once completed
- Increased cash position along with potential proceeds from sale of vitaCare provide strong cash runway

Financing Update
- Plan to pay down a total of $50M principal under financing agreement by end of 1Q21
- Updated total minimum net revenue covenants for ANNOVERA, IMVEXXY and BIJUVA
  - While not formal guidance, TXMD believes the covenants have been set at an achievable level given the current state of the COVID-19 pandemic and provide sufficient headroom to avoid further adjustments

<table>
<thead>
<tr>
<th></th>
<th>1Q21</th>
<th>2Q21</th>
<th>3Q21</th>
<th>4Q21</th>
</tr>
</thead>
<tbody>
<tr>
<td>Revised (Jan &amp; Feb 2021)</td>
<td>$17M</td>
<td>$20M</td>
<td>$23M</td>
<td>$26.5M</td>
</tr>
<tr>
<td>Previous (Aug 2020)</td>
<td>$25M</td>
<td>$37.5M</td>
<td>$47.5M</td>
<td>$57.5M</td>
</tr>
</tbody>
</table>
4Q20 Financial Overview
Quarterly Net Revenue Trends

4Q20 Highlights

- Overall Net Revenue from Products increased 30% quarter over quarter:
  - ANNOVERA net revenue increased 42%
    - Average net revenue per unit $1,336\(^{(1)}\)
  - IMVEXXY net revenue increased 29%
    - Average net revenue per unit $54\(^{(1)}\)
  - BIJUVA net revenue increased 36%
    - Average net revenue per unit $52\(^{(1)}\)

Total net product revenue may not add due to rounding.

(1) Average net revenue per unit calculated based on units sold to wholesalers and pharmacies divided into net revenue for the quarter.
Financial Results: Comparison 3Q 2020 to 4Q 2020

Comparison of Key Financial Statement Items

<table>
<thead>
<tr>
<th></th>
<th>4Q20</th>
<th>3Q20</th>
<th>Increase (Decrease)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Balance Sheet (1)</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cash</td>
<td>$80,486</td>
<td>$79,634</td>
<td>$852</td>
</tr>
<tr>
<td>Long-term Debt</td>
<td>$237,698</td>
<td>$237,051</td>
<td>$647</td>
</tr>
<tr>
<td><strong>Income Statement</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Net Product Revenue</td>
<td>$22,577</td>
<td>$17,343</td>
<td>$5,234</td>
</tr>
<tr>
<td>Gross Profit from Products</td>
<td>$16,996</td>
<td>$14,064</td>
<td>$2,932</td>
</tr>
<tr>
<td>Gross Margin %</td>
<td>75%</td>
<td>81%</td>
<td>(6%)</td>
</tr>
<tr>
<td><strong>Total Operating Expenses (2)</strong></td>
<td>$42,948</td>
<td>$37,061</td>
<td>$5,887</td>
</tr>
<tr>
<td>Net loss</td>
<td>($42,088)</td>
<td>($32,611)</td>
<td>($9,477)</td>
</tr>
<tr>
<td><strong>Statement of Cash Flow</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Net Cash Used In Operating Activities</td>
<td>($30,321)</td>
<td>($34,049)</td>
<td>($3,728)</td>
</tr>
</tbody>
</table>

- Gross Margin of 75%
  - Impacted by write-offs of finished goods inventory for ANNOVERA $0.8M, IMVEXXY $0.5M and BIJUVA $0.5M
- Operating expenses in-line with goal of $80M for 2H20, excluding non-cash items and incentives totaling $13M
  - Plan to maintain an efficient cost base that can be leveraged as revenue grows
  - Investments expected to be made in 2021 to improve supply chain, enhance marketing and strengthen IT capabilities related to commercial initiatives
- Net cash used in operating activities decreased by $3.7M from $34M in 3Q20 to $30.3M in 4Q20

---

(1) Balance Sheet as of quarter end.
(2) Excluding non-cash items and incentives of $13M.
Financial Accomplishments

- Reduced operating expenses and cash burn by successfully meeting our goal of $80 million in op-ex for the second half of 2020, excluding non-cash items and incentives totaling $13M
  - Reduced net cash used in operating activities to $30.3M for the 4Q20

- Strengthened our balance sheet by raising $180M in cash and committing to pay down $50M in debt

- Revised our revenue covenants to what we believe are achievable levels given the current state of the COVID-19 Pandemic
Commercial Performance and Growth Drivers
Payor Progress: Maintained all Major Payors Across Product Portfolio

<table>
<thead>
<tr>
<th>Payor</th>
<th>Coverage November 1, 2020</th>
<th>Coverage March 1, 2021</th>
</tr>
</thead>
<tbody>
<tr>
<td>Commercial</td>
<td>62% UR, 74%(^{(1)})</td>
<td>70% UR, 79%(^{(1)})</td>
</tr>
<tr>
<td>Medicaid</td>
<td>57%(^{(2)})</td>
<td>57%</td>
</tr>
<tr>
<td>Department of Defense</td>
<td>On Formulary</td>
<td>On Formulary</td>
</tr>
<tr>
<td>Commercial</td>
<td>69%</td>
<td>76%</td>
</tr>
<tr>
<td>Part D</td>
<td>37%(^{(3)})</td>
<td>37%+(^{(3)})</td>
</tr>
<tr>
<td>Commercial</td>
<td>71%</td>
<td>75%</td>
</tr>
</tbody>
</table>

**Recent changes to access:**

- Increases in coverage due to increased lives in plans where TXMD products have access
- ANNOVERA unrestricted commercial access improved to 70%, IMVEXXY commercial access improved to 76% and BIJUVA commercial access improved to 75%
- ANNOVERA Medicaid lives continue to grow, now up to 68M

Source: MMIT as of February 1, 2021.

Note: (1) 79% covered with prior authorization (PA) / step edit. (2) ANNOVERA Medicaid Note: estimated coverage will increase from 41% to 57% on 1/1/21 when MediCal controls all the Medicaid Managed Care formularies in California. (3) Includes lives with PA to indication only. UR=unrestricted.
ANNOVERA: Unique Opportunity to Create a New Segment within Birth Control
ANNOVERA Continued Growth Trajectory: 15% Unit Increase from Q4 over Q3

Source: Prescription data per Symphony Health PHAST Data.

ANNOVERA 4Q20 Performance Drivers

- Access to prescribers improving for sales force
- Consumer campaign launched in July beginning to take hold
- Launched celebrity spokesperson in December
- Continued to see growth in number of prescribers
- Net revenue per unit remained strong at $1,336
- 4Q20 net revenue increased 42% from 3Q20
Leading Indicator of Potential Future Growth: ANNOVERA
Writers Continue to Grow

Key Takeaways

- Growth across all categories of targets that are sales force driven
- Growth across non-targets that are marketing driven
Leading Indicator of Potential Future Growth: ANNOVERA Consumer Relevance, Impact and Intent

Relevance:
2.7B Impressions

Just Say Vagina campaign placement in top media outlets

Impact:
Above Benchmark

- Above industry benchmark click through rates 0.29% vs. 0.25%
- Site traffic 10,000 people per day

Intent: Climbing

Brand lift studies conducted show an average of 60% intend to request ANNOVERA

All trademarks are property of their respective owners.
Focus is on Execution to Improve Trajectory

What is working: cost effective ways to get patients and prescribers interested

- Build of ANNOVERA consumer demand through advertising and influencer marketing
  - 2.7B impressions of initial PR campaign
  - Over 10,000 visits a day to ANNOVERA.com
- Reaching prescribers remotely with new educational formats
  - Fireside chats
- Growth in numbers of prescribers writing each quarter

What we are working on accelerating: conversion of interest and initial action

- Increased and faster pull through of consumer interest to prescription
- Moving prescribers up the adoption chain from trialists to champions
• From launch until 12/31/20, ~16,000 women have filled an Rx for ANNOVERA

• The aggregate amount of women on therapy created significant value for TXMD, because a full year of revenue (13 fills) is realized when the prescription is dispensed

• In addition, our strong refill rates of ~50% will create a significant future revenue opportunity
LARCs encouraged as front-line therapy

- LARC’s growing at a ~15% 8-year CAGR\(^{(1)}\)

But LARCs are not for everyone

- ~47% patients rejected IUDs/Implants due to procedure\(^{(2)}\)
- Almost half of GYNs and most PCPs do not offer IUDs/Implants

Solution: ANNOVERA

A Long-lasting option that can be used by all prescribers and patients

Note: (1) Based on company filings; (2) Internal research findings
ANNOVERA Removes Barriers to Long-Acting Birth Control by Removing the Need for a Procedure like ColoGuard did for Colorectal Screening

All logos are property of their respective owners.
ANNOVERA Goal: Become a New Segment in Birth Control

Short-Acting Decline
-4.2% CAGR\(^{(1)}\)

Long-Acting Growth
+15% CAGR\(^{(1)}\)

Annual,
Procedure Free

Daily | Weekly | Monthly | 3 mo. injection | 1 Year | 3-10 Years

SHORT-ACTING

Market Void

LONG-ACTING

Note: \(^{(1)}\) Based on company filings.
## Product Used Before ANNOVERA

### ANNOVERA is gaining market share from all products

<table>
<thead>
<tr>
<th>Users’ Previous Method</th>
<th>vitaCare Patient Data, n=276</th>
<th>Claimed from HCP Survey Q420&lt;sup&gt;(1)&lt;/sup&gt;</th>
</tr>
</thead>
<tbody>
<tr>
<td>Oral Contraception</td>
<td>24%</td>
<td>40%</td>
</tr>
<tr>
<td>IUD</td>
<td>9%</td>
<td>18%</td>
</tr>
<tr>
<td>Patch</td>
<td>4%</td>
<td>9%</td>
</tr>
<tr>
<td>Implant</td>
<td>7%</td>
<td>6%</td>
</tr>
<tr>
<td>Injection</td>
<td>6%</td>
<td>4%</td>
</tr>
<tr>
<td>NuvaRing (or Generic)</td>
<td>44%</td>
<td>23%</td>
</tr>
</tbody>
</table>

Note: (1) Internal research

- Base: HCPs with switch prescriptions (ANNOVERA: Q1’20=98; Q4’20=109; NuvaRing: Q1’20=144; Q4’20=145; Oral Pill: Q1’20=145; Q4’20=145; IUD: Q1’20=145; Q4’20=145)
- Q420. Thinking of the patients who were switched to a different form of birth control in the past 30 days to each of the following, which forms of birth control were they most commonly switched from?
ANNOVERA Net Revenues are Significant at Small Market Share Percentages

**Contraception Market Size**
- $7 billion market size
- 28 million new prescriptions annually
- 18 million women

**Time to Achieve 4-5% Market Share**
- **Lo-Loestrin FE**
  - ~4 years
- **NuvaRing**
  - ~5 years
- **Cologuard**
  - ~5 years

**ANNOVERA Gross Revenue at Different Example Market Shares (WAC: $2,000)**
- 1%: 180K Rx, ~$360M
- 2%: 360K Rx, ~$720M
- 3%: 540K Rx, ~$1.1B
- 4%: 720K Rx, ~$1.4B
- 5%: 900K Rx, ~$1.8B

Note: All trademarks are the property of their respective owners. Source: Symphony Health PHAST Data
IMVEXXY: Fastest Growing Branded Product in Vulvar Vaginal Atrophy Category
IMVEXXY Performance Drivers

IMVEXXY 4Q20 Performance Drivers

- Access to prescribers improving for sales force, but still well below pre-COVID-19
- ~6% increase in prescribers writing a prescription in 4Q20 compared to 3Q20 (13,500 vs 12,700)
  - ~9% increase in prescribers writing a new prescription (NRx) in the 4Q20 over the 3Q20
- Net revenue per unit improved to $54
- 4Q20 net revenue increased 29% from Q320

Source: Prescription data per Symphony Health PHAST Data.
2021 IMVEXXY Strategic Initiatives

Realize Higher Net Pricing
- Effective January 1st, cash pay program and high-deductible patients co-pay increased from $50 to $75

Increase Volumes and Market Share through PBM
- Effective January 1st, only branded product covered at preferred status at top PBM (~20% of commercial lives)
  - Premarin® Cream, Osphena®, Intrarosa® and Estring® brands are all excluded and only IMVEXXY will be covered @ Tier 2
  - IMVEXXY will now be cheaper to the patient for all branded TRx in 2021 at this PBM

Market Share Gains through Retail Partnerships
- Continued focus on patient adherence and driving higher refill rates across all distribution channels
  - For patients without the preferred PBM pharmacy coverage, we are increasing the use of the co-pay card in retail with chain store and Bio-Ignite partnerships

All trademarks are the property of their respective owners.
As expected, short-term impact on volume in January:

- Changes to $75
- Improvements in adjudication, net revenue per unit and net revenue
- To date, ~$17 improvement in cost per fill for those who used the copay program
- Short-term impact on volume in January from high deductible and cash pay customers in-line with expectations

Data Source: Prescription data per Symphony Health PHAST Data.
2021 is Our Year to Inspire and Drive Action with an Ownable and Differentiated Campaign for IMVEXXY

Q1: PATIENT TESTIMONIALS

- Launched 2/10 on Facebook
- Designed to help women understand that symptoms of menopause are common and normal
- 9 total videos will be launched

Q2: NEW CAMPAIGN

- "REIGN"
  - Grounded in Self Care. Educates menopausal women about overall vaginal health and taking charge of this new life stage
  - 75% of women who started Reign in quantitative testing watched the full video\(^1\)

\(^1\) Reference: IMVEXXY Campaign Quantitative Test, N=150, Oct. 2020
BIJUVA: First and Only FDA-Approved Bio-Identical Solution in Vasomotor Symptoms (VMS) Market
BIJUVA Volume Increased with Bio-Ignite Focus

BIJUVA Quarterly Performance

BIJUVA 4Q20 Performance Drivers

- Targeted approach with supporting Bio-Ignite to maintain brand loyalists with 7 sales representatives
- ~3% increase in prescribers writing a prescription in 4Q20 compared to 3Q20 (4,750 vs 4,600)
  - Maintained NRx
- Net revenue per unit improved to $52
- 4Q20 net revenue increased 36% from Q320

Data Source: Prescription data per Symphony Health PHAST Data.
Summary

- Transformed our capital structure
- Improved our balance sheet
- Updated our net revenue covenants
- Framework is in place to accelerate both ANNOVERA and IMVEXXY adoption throughout 2021
- vitaCare divesture progressing
- Well positioned to continue our growth to EBITDA break even, anticipated in the first half of 2022
Q&A
Appendix
ANNOVERA Launch in Perspective

ANNOVERA growing despite pandemic challenges

In Person Details at less than 50% of 2019 baseline

ANNOVERA holding despite launch brand stagnation

Biopharma In-Person Details (1)

- Specialty continues to lead with 38% vs. baseline
- Primary Care and Oncology in-person details are at 32% and 16% of baseline, respectively

Comparison of Launches in 2020 (2)

- Average Growth % Month over Month
- Annovera Growth % Month over Month

(1) IQVIA; (2) Symphony Health Solutions PHAST Data
ANNOVERA Leading Indicators for Potential Future Growth

**2020 ANNOVERA Quarterly TRx**

<table>
<thead>
<tr>
<th>Quarter</th>
<th>TRx</th>
</tr>
</thead>
<tbody>
<tr>
<td>1Q20</td>
<td>2,361</td>
</tr>
<tr>
<td>2Q20</td>
<td>2,410</td>
</tr>
<tr>
<td>3Q20</td>
<td>5,160</td>
</tr>
<tr>
<td>4Q20</td>
<td>5,950</td>
</tr>
</tbody>
</table>

**2021 ANNOVERA Weekly TRx**

<table>
<thead>
<tr>
<th>Date</th>
<th>TRx</th>
</tr>
</thead>
<tbody>
<tr>
<td>1/1/21</td>
<td>342</td>
</tr>
<tr>
<td>1/8/21</td>
<td>404</td>
</tr>
<tr>
<td>1/15/21</td>
<td>480</td>
</tr>
<tr>
<td>1/22/21</td>
<td>507</td>
</tr>
<tr>
<td>1/29/21</td>
<td>539</td>
</tr>
<tr>
<td>2/5/21</td>
<td>494</td>
</tr>
<tr>
<td>2/12/21</td>
<td>503</td>
</tr>
</tbody>
</table>

Source: Prescription data per Symphony Health PHAST Data.
ANOVERA Launch Metrics: Value of Each Patient and Total Number of Women on Therapy

- ANOVERA is the only annual prescription product on the market today
  - When an ANOVERA prescription is filled, it represents 13 monthly equivalent fills, providing a woman contraception for a year
  - For comparison, other monthly contraceptive products are filled on average 4-6 times per year
- For each ANOVERA prescription, TXMD receives payment for all 13 monthly equivalent fills upfront from a net revenue perspective
  - This differentiation significantly increases the value of every prescription of ANOVERA and represents a 2-3x greater expected value than competing contraceptive products over the course of a calendar year
- Because of ANOVERA’s unique annual use, the number of aggregate women on therapy compounds, providing TXMD with an attractive, growing pipeline of refill opportunities over time

Source: Symphony Prescriber level data.
13 TRx of Net Revenue Upfront: Significant Increase in Annual Value of Patient

<table>
<thead>
<tr>
<th>ANNOVERA Annual Value of Patient</th>
</tr>
</thead>
<tbody>
<tr>
<td>1 TRx = Current Net Revenue of $1,336</td>
</tr>
<tr>
<td>13 monthly equivalent TRx received upfront</td>
</tr>
<tr>
<td>Current Annual Value of Patient = $1,336</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Monthly Products Annual Value of Patient</th>
</tr>
</thead>
<tbody>
<tr>
<td>1 TRx = Net Revenue of $80-$100</td>
</tr>
<tr>
<td>1 TRx received upfront</td>
</tr>
<tr>
<td>Average fill rates during year: 4-6 fills</td>
</tr>
<tr>
<td>Annual Value of Patient = $320 - $600</td>
</tr>
</tbody>
</table>

Key Takeaway

Every ANNOVERA patient produces 2-3x the net revenue of other contraceptive products on an annual basis.
ANNOVERA Launch Curve: Aggregate Women on Therapy

- From launch until 12/31/20, ~16,000 women have filled an Rx for ANNOVERA
- The aggregate amount of women on therapy created significant value for TXMD, because a full year of revenue (13 fills) is realized when the prescription is dispensed
- In addition, our strong refill rates of ~50% will create a significant future revenue opportunity

Symphony Health Solutions PHAST Data.
## Symphony Monthly TRx: Spec Pharma Product Launches During COVID-19

### Launch Rank by 4Q2020 TRx

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>SLYND</td>
<td>Contraception</td>
<td>76,004</td>
<td>28,150</td>
<td>24,451</td>
<td>23,403</td>
<td>21,113</td>
<td>20,656</td>
<td>18,658</td>
<td>17,511</td>
<td>15,086</td>
<td>14,041</td>
</tr>
<tr>
<td>Aklief</td>
<td>Acne</td>
<td>56,357</td>
<td>21,544</td>
<td>17,327</td>
<td>17,486</td>
<td>14,285</td>
<td>14,406</td>
<td>12,430</td>
<td>10,174</td>
<td>7,687</td>
<td>5,951</td>
</tr>
<tr>
<td>ORILISSA</td>
<td>Endometriosis</td>
<td>46,604</td>
<td>16,233</td>
<td>15,011</td>
<td>15,360</td>
<td>15,032</td>
<td>15,549</td>
<td>15,114</td>
<td>15,385</td>
<td>14,788</td>
<td>15,338</td>
</tr>
<tr>
<td>BAQSIMI</td>
<td>Diabetes recovery</td>
<td>43,891</td>
<td>15,563</td>
<td>13,303</td>
<td>15,025</td>
<td>15,252</td>
<td>16,182</td>
<td>13,641</td>
<td>11,217</td>
<td>9,417</td>
<td>8,751</td>
</tr>
<tr>
<td>RINVOQ</td>
<td>Arthritis</td>
<td>36,810</td>
<td>13,369</td>
<td>11,622</td>
<td>11,819</td>
<td>10,989</td>
<td>10,190</td>
<td>10,117</td>
<td>9,079</td>
<td>7,962</td>
<td>7,434</td>
</tr>
<tr>
<td>DAYVIGO</td>
<td>Sleep aid</td>
<td>21,303</td>
<td>8,605</td>
<td>6,762</td>
<td>5,936</td>
<td>4,242</td>
<td>2,911</td>
<td>1,644</td>
<td>659</td>
<td>5</td>
<td></td>
</tr>
<tr>
<td>GVOKE HYDROPEN &amp; SYRINGE</td>
<td>Diabetes recovery</td>
<td>18,010</td>
<td>6,364</td>
<td>5,583</td>
<td>6,063</td>
<td>5,874</td>
<td>5,868</td>
<td>4,840</td>
<td>2,791</td>
<td>2,396</td>
<td>2,028</td>
</tr>
<tr>
<td>NEXLETOL</td>
<td>Cholesterol</td>
<td>16,642</td>
<td>6,611</td>
<td>5,245</td>
<td>4,786</td>
<td>3,806</td>
<td>2,795</td>
<td>2,063</td>
<td>1,252</td>
<td>470</td>
<td>157</td>
</tr>
<tr>
<td>REYVOW</td>
<td>Migrane</td>
<td>8,516</td>
<td>3,120</td>
<td>2,657</td>
<td>2,739</td>
<td>2,539</td>
<td>2,577</td>
<td>2,514</td>
<td>2,266</td>
<td>2,006</td>
<td>1,850</td>
</tr>
<tr>
<td>ANNOVERA</td>
<td>Contraception</td>
<td>5,952</td>
<td>2,014</td>
<td>1,849</td>
<td>2,089</td>
<td>1,749</td>
<td>1,877</td>
<td>1,534</td>
<td>1,169</td>
<td>670</td>
<td>574</td>
</tr>
<tr>
<td>PHEXXI</td>
<td>Contraception</td>
<td>4,382</td>
<td>1,878</td>
<td>1,398</td>
<td>1,106</td>
<td>458</td>
<td>3</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ONGENTYS</td>
<td>Movement disorders</td>
<td>1,170</td>
<td>611</td>
<td>373</td>
<td>186</td>
<td>24</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>VYEPTI</td>
<td>Migrane</td>
<td>268</td>
<td>95</td>
<td>89</td>
<td>84</td>
<td>65</td>
<td>73</td>
<td>58</td>
<td>55</td>
<td>62</td>
<td>8</td>
</tr>
<tr>
<td>TWIRLA</td>
<td>Contraception</td>
<td>118</td>
<td>104</td>
<td>5</td>
<td>9</td>
<td>3</td>
<td>1</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Symphony Health Solutions PHAST Data.
Payor Progress and Birth Control State Laws Supporting Low Out of Pocket Cost

- ANNOVERA costs the same or less than the generic for NuvaRing on an annual basis\(^{(1)}\)

<table>
<thead>
<tr>
<th>Patient Cost</th>
<th># of Patients</th>
<th>% of Patients</th>
</tr>
</thead>
<tbody>
<tr>
<td>$0</td>
<td>2,069</td>
<td>79%</td>
</tr>
<tr>
<td>$1 - $60</td>
<td>432</td>
<td>17%</td>
</tr>
<tr>
<td>$61 or greater</td>
<td>121</td>
<td>4%</td>
</tr>
<tr>
<td>Grand Total</td>
<td>2,622</td>
<td>100.00%</td>
</tr>
</tbody>
</table>

Note: (1) Internal data from a cross section of commercial payors.
ESG is Important to TherapeuticsMD

- While TherapeuticsMD has significant milestones to achieve prior to profitability, it is committed to making a positive impact in our communities, particularly for women.
- TherapeuticsMD’s mission is to improve the quality of life for women.

In 2021:

- TherapeuticsMD has taken significant ESG actions in the past, but plans to do more on a go-forward basis, with enhanced ESG reporting.
- TherapeuticsMD leadership has organized an ESG committee to set in motion initiatives that will further improve our communities into the future.
TherapeuticsMD Environmental, Social, and Governance

- Environmental
  - TherapeuticsMD recently moved headquarters to a facility that has **automated features that allow TherapeuticsMD to be better environmental stewards**, including:
    - Automatic lighting, water conservation fixtures, etc.
    - Reduction in the number of offices and conference rooms to reduce the footprint that needs to be cooled and lighted, opting instead to build conference features into offices
  - TherapeuticsMD **products are designed to reduce the amount of waste:**
    - ANNOVERA’s use for 13 cycles eliminates 12 silicone rings that would otherwise end up in landfills.
    - IMVEXXY was designed specifically to avoid needing insertion with a plastic applicator
TherapeuticsMD Environmental, Social, and Governance

- Social
  - TherapeuticsMD’s mission is to **improve the quality of life for women**, a traditionally underrepresented group
    - TherapeuticsMD contracts with Title X providers to improve contraceptive access for women
    - Co-pay cards provide pricing relief for women in need of TXMD products
  - TherapeuticsMD is **committed to diverse hiring:**
    - 64% of TherapeuticsMD’s workforce is women
    - 44% of TherapeuticsMD’s workforce comprises underrepresented minorities (race or ethnicity)
TherapeuticsMD Environmental, Social, and Governance

- **Governance**
  - Recently increased *gender and racial diversity* representation on the Company’s Board of Directors
  - Would meet **Nasdaq’s proposed diversity requirements** of one woman and one under-represented minority/LGBTQ+ person on the board